The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor

This publication has 13 references indexed in Scilit:

• Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
  Circulation, 1986
• Spectral studies on structure-activity relationships of thromboxane synthesis inhibitors
  European Journal of Biochemistry, 1986
• Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548)
  Thrombosis Research, 1986
• Cv-4151 — a potent, selective thromboxane A2synthetase inhibitor
  Thrombosis Research, 1986
• Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acids
  Journal of Medicinal Chemistry, 1985
• Inhibition of thromboxane biosynthesis in serum: Limitations of the measurement of immunoreactive 6-KETO-PGF1α
  Thrombosis Research, 1984
• PHARMACOLOGICAL INTERACTIONS BETWEEN PROSTACYCLIN AND THROMBOXANES
  British Medical Bulletin, 1983
• THE PROSTACYCLIN-THROMBOXANE A2 BALANCE: PATHOPHYSIOLOGICAL AND THERAPEUTIC IMPLICATIONS
  British Medical Bulletin, 1983
• Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets
  European Journal of Pharmacology, 1983
• CV-3988 - A specific antagonist of platelet activating factor (PAF)
  Life Sciences, 1983